RxDoctor Payments Data

Ahmad Halawa, MD

Clinical Cardiac Electrophysiology · New Brunswick, NJNPI 1760675847

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (45.8%), grants and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Medtronic at 45.0% of the total. Reporting peaked in 2019 at $9,544 and has fallen 96.3% since, to $357 in 2025.

$20,081in general payments, 2019–2025

Across 109 payments — averaging $184.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Boston Scientific$4K
  • Abbott$3K
  • Medical Device Business Services, Inc.$2K
  • Biosense Webster, Inc.$857
  • Impulse Dynamics (USA) Inc.$53
  • plus $268 from 9 others

What the payments were for

  • Grants$5,83329%
  • Travel & lodging$9,20146%
  • Food & beverage$4,62923%
  • Education$4172%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,081 in reported general payments places this provider in the 60th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$137,363
Medicare patients
867
Services billed
2,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$54,491
XareltoRivaroxaban22$20,891
Amiodarone Hcl133$2,278
Metoprolol Succinate139$1,727
Flecainide Acetate14$1,180
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$454
Mupirocin48$401
Metoprolol Tartrate46$164
Furosemide29$111
Potassium Chloride12$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$54,49159 claims
Johnson & JohnsonXarelto$31$20,89122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →